文献速递临床试验与 GCP流行病学与生物统计

轻度降低射血分数心肌梗死后的β受体阻滞剂:随机对照试验的个体患者数据荟萃分析

β blockers after myocardial infarction with mildly reduced ejection fraction: an individual patient data meta-analysis of randomised controlled trials.
PubMed 文献 · Lancet · 2025-08-30

该研究为四项随机对照试验的个体患者数据荟萃分析,纳入1885例急性心肌梗死且左心室射血分数轻度降低(40-49%)且无心力衰竭病史或体征的患者。β受体阻滞剂组主要复合终点(全因死亡、新发心肌梗死或心力衰竭)发生106例(32.6事件/1000患者年),对照组129例(43.0事件/1000患者年),风险比0.75(95%CI 0.58-0.97;p=0.031)。

要点

  • 在心肌梗死伴射血分数轻度降低且无心力衰竭的患者中,β受体阻滞剂与主要复合终点风险降低相关(HR 0.75)。
  • 主要复合终点包括全因死亡、新发心肌梗死或心力衰竭,β受体阻滞剂组发生106例 vs 对照组129例。
  • 试验间(交互作用p=0.95)及入组国家间(交互作用p=0.98)未见异质性。

核心结论

  • 在急性心肌梗死伴左心室射血分数轻度降低且无心力衰竭病史或临床体征的患者中,β受体阻滞剂治疗与全因死亡、新发心肌梗死或心力衰竭复合终点的降低相关。

研究设计与样本

  • 研究为个体患者水平荟萃分析,纳入四项近期随机对照试验中左心室射血分数轻度降低且无心力衰竭病史或体征的患者。
  • 纳入标准为测试口服β受体阻滞剂长期疗效(中位随访>1年)的随机对照试验,患者近期发生心肌梗死(随机化在14天内)且左心室射血分数轻度降低。
  • 系统综述(2020年1月1日至2025年6月26日)未发现进一步研究。
  • 采用一阶段固定效应Cox比例风险回归模型评估β受体阻滞剂对预设主要复合终点的治疗效果,所有终点均独立裁定。
  • 该荟萃分析在PROSPERO注册(CRD420251023480)。

主要发现

  • 共纳入1885例心肌梗死伴左心室射血分数轻度降低患者:REBOOT试验979例,BETAMI试验422例,DANBLOCK试验430例,CAPITAL-RCT试验54例。
  • β受体阻滞剂组991例,对照组(未使用β受体阻滞剂)894例。
  • 主要复合终点在β受体阻滞剂组发生106例(32.6事件/1000患者年),对照组发生129例(43.0事件/1000患者年)(风险比0.75[95%CI 0.58-0.97];p=0.031)。
  • 试验间未见异质性(试验与治疗交互作用p=0.95),入组国家间亦未见异质性(交互作用p=0.98)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The effects of β-blocker therapy on clinical outcomes in patients with myocardial infarction and mildly reduced (40-49%) left ventricular ejection fraction (LVEF) are largely unknown. Four recently conducted randomised trials tested the efficacy of β blockers after a recent myocardial infarction in patients without reduced LVEF (LVEF ≥40%). However, none were individually powered to assess these effects in the subgroup of patients with mildly reduced LVEF. We aimed to assess the efficacy of β blockers in patients with myocardial infarction and mildly reduced LVEF during the index hospitalisation. METHODS: We conducted an individual patient-level meta-analysis of patients with mildly reduced LVEF and no history or signs of heart failure from four recent clinical trials. These studies were included because they were randomised controlled trials testing long-term effects (median follow-up >1 year) of oral β-blocker therapy in patients who recently had a myocardial infarction (randomisation within 14 days) and had mildly reduced LVEF. No further studies were found in a systematic review (Jan 1, 2020 to June 26, 2025). A one-stage, fixed-effects, Cox proportional hazards regression model was used to assess the treatment effect of β blockers on the predefined primary composite endpoint of all-cause death, new myocardial infarction, or heart failure. All endpoints were independently adjudicated. This meta-analysis was registered with PROSPERO (CRD420251023480). FINDINGS: 1885 patients with myocardial infarction and mildly reduced LVEF were included in the meta-analysis: 979 from the REBOOT trial, 422 from the BETAMI trial, 430 from the DANBLOCK trial, and 54 from the CAPITAL-RCT trial. Overall, 991 patients were assigned to β blockers and 894 to control (no β blockers). The primary composite endpoint occurred in 106 patients (32·6 events per 1000 patient-years) in the β-blocker group and 129 patients (43·0 per 1000 patient-years) in the no β-blocker group (hazard ratio 0·75 [95% CI 0·58-0·97]; p=0·031). No heterogeneity between the trials (trial-by-treatment pinteraction=0·95) or between countries of enrolment was observed (pinteraction=0·98). INTERPRETATION: In patients with acute myocardial infarction with mildly reduced LVEF without history or clinical signs of heart failure, β-blocker therapy was associated with a reduction in the composite of all-cause death, new myocardial infarction, or heart failure. These results extend the known benefits of these agents in patients with myocardial infarction with reduced LVEF to the subgroup with mildly reduced LVEF. FUNDING: Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Danish Heart Foundation, Novo Nordisk Foundation, South-Eastern Norway Regional Health Authority, and Research Council of Norway.

来源:Lancet,查看原文。版权归原作者所有。

引用

  1. Rossello X, Prescott EIB, Kristensen AMD, et al. β blockers after myocardial infarction with mildly reduced ejection fraction: an individual patient data meta-analysis of randomised controlled trials. Lancet. 2025. PMID: 40897190. doi:10.1016/S0140-6736(25)01592-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。